GlassScriptPhysician profile
Muhammad Siddique
NPI 1720217714
$466.06
in general payments reported to CMS, 2019-2025
9 companies · $60.69 in 2025
The $60.69 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.22 · 2022: $77.42 · 2023: $201 · 2024: $99.94 · 2025: $60.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $123.12 | 2023 | Lunsumio, Polivy |
| Abbott Laboratories | $99.94 | 2024 | Xience Skypoint |
| Celgene Corporation | $57.35 | 2022-2023 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $50.82 | 2021-2022 | |
| Janssen Biotech, INC. | $38.99 | 2023 | Darzalex |
| Eisai INC. | $30.03 | 2022-2025 | |
| Abbvie INC. | $24.59 | 2025 | |
| Lilly USA, LLC | $21.72 | 2025 | Jaypirca, Verzenio |
| Exelixis INC. | $19.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Siddique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.